Natera, Inc. (NASDAQ:NTRA) Position Trimmed by Truist Financial Corp

Truist Financial Corp trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 18.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 37,166 shares of the medical research company’s stock after selling 8,644 shares during the quarter. Truist Financial Corp’s holdings in Natera were worth $2,328,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. RiverPark Advisors LLC purchased a new position in Natera during the 4th quarter worth approximately $27,000. Harvest Fund Management Co. Ltd purchased a new position in Natera during the 3rd quarter worth approximately $44,000. Oliver Lagore Vanvalin Investment Group grew its position in Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Natera during the 3rd quarter worth approximately $111,000. Finally, CWM LLC grew its position in Natera by 41.8% during the 4th quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock worth $117,000 after purchasing an additional 550 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research reports. Craig Hallum initiated coverage on shares of Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 target price for the company. Piper Sandler lifted their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and lifted their target price for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Canaccord Genuity Group lifted their target price on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 35,307 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the transaction, the insider now owns 204,218 shares in the company, valued at approximately $15,334,729.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Herm Rosenman sold 93,901 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $69.37, for a total value of $6,513,912.37. Following the sale, the director now owns 61,685 shares of the company’s stock, valued at $4,279,088.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Rabinowitz sold 35,307 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the sale, the insider now directly owns 204,218 shares in the company, valued at approximately $15,334,729.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 380,750 shares of company stock worth $31,864,820. 7.60% of the stock is currently owned by company insiders.

Natera Stock Down 1.5 %

Natera stock opened at $95.66 on Thursday. The firm has a market cap of $11.55 billion, a price-to-earnings ratio of -25.24 and a beta of 1.38. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The firm has a fifty day moving average price of $91.82 and a two-hundred day moving average price of $70.64.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. As a group, analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.